PULMONX CORPORATION Selling, General and Administrative Expense
PULMONX CORPORATION (LUNG) reported Selling, General and Administrative Expense of $21.77 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-04
- PULMONX CORPORATION selling, general and administrative expense for the quarter ending 2026-06-30 was $21.77M, a 18.49% decline year-over-year.
- PULMONX CORPORATION selling, general and administrative expense for the quarter ending 2026-03-31 was $24.10M, a 7.83% decline year-over-year.
- PULMONX CORPORATION selling, general and administrative expense for the quarter ending 2025-12-31 was $22.86M, a 15.35% decline year-over-year.
- PULMONX CORPORATION selling, general and administrative expense for the quarter ending 2025-09-30 was $25.60M, a 0.74% increase year-over-year.
- PULMONX CORPORATION selling, general and administrative expense for fiscal 2025 was $101.31M, a 0.81% decline from fiscal 2024.
- PULMONX CORPORATION selling, general and administrative expense for fiscal 2024 was $102.14M, a 7.96% increase from fiscal 2023.
- PULMONX CORPORATION selling, general and administrative expense for fiscal 2023 was $94.61M, a 13.84% increase from fiscal 2022.
- PULMONX CORPORATION selling, general and administrative expense for fiscal 2022 was $83.11M, a 18.94% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $21.77M 10-Q · filed 2026-08-04 | $45.87M 10-Q · filed 2026-08-04 | $68.73M derived: sum of 3 quarters · filed 2026-08-04 | $94.33M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2026-03-31 | $24.10M 10-Q · filed 2026-05-04 | $46.96M derived: sum of 2 quarters · filed 2026-05-04 | $72.56M derived: sum of 3 quarters · filed 2026-05-04 | $99.26M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-12-31 | $22.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $48.46M derived: sum of 2 quarters · filed 2026-03-10 | $75.16M derived: sum of 3 quarters · filed 2026-08-04 | $101.31M 10-K · filed 2026-03-10 | ||
| 2025-09-30 | $25.60M 10-Q · filed 2025-11-12 | $52.30M derived: sum of 2 quarters · filed 2026-08-04 | $78.45M 10-Q · filed 2025-11-12 | $105.46M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-06-30 | $26.70M 10-Q · filed 2026-08-04 | $52.85M 10-Q · filed 2026-08-04 | $79.86M derived: sum of 3 quarters · filed 2026-08-04 | $105.27M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-03-31 | $26.15M 10-Q · filed 2026-05-04 | $53.16M derived: sum of 2 quarters · filed 2026-05-04 | $78.57M derived: sum of 3 quarters · filed 2026-05-04 | $103.88M derived: sum of 4 quarters · filed 2026-05-04 | ||
| 2024-12-31 | $27.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $52.42M derived: sum of 2 quarters · filed 2026-03-10 | $77.73M derived: sum of 3 quarters · filed 2026-03-10 | $102.14M 10-K · filed 2026-03-10 | ||
| 2024-09-30 | $25.41M 10-Q · filed 2025-11-12 | $50.73M derived: sum of 2 quarters · filed 2025-11-12 | $75.13M 10-Q · filed 2025-11-12 | $99.55M derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | $25.31M 10-Q · filed 2025-08-01 | $49.72M 10-Q · filed 2025-08-01 | $74.14M derived: sum of 3 quarters · filed 2025-08-01 | $98.13M derived: sum of 4 quarters · filed 2025-08-01 | ||
| 2024-03-31 | $24.40M 10-Q · filed 2025-05-02 | $48.83M derived: sum of 2 quarters · filed 2025-05-02 | $72.81M derived: sum of 3 quarters · filed 2025-05-02 | $96.28M derived: sum of 4 quarters · filed 2025-05-02 | ||
| 2023-12-31 | $24.42M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $48.41M derived: sum of 2 quarters · filed 2025-02-25 | $71.87M derived: sum of 3 quarters · filed 2025-02-25 | $94.61M 10-K · filed 2025-02-25 | ||
| 2023-09-30 | $23.98M 10-Q · filed 2024-11-01 | $47.45M derived: sum of 2 quarters · filed 2024-11-01 | $70.18M 10-Q · filed 2024-11-01 | $92.09M derived: sum of 4 quarters · filed 2024-11-01 | ||
| 2023-06-30 | $23.46M 10-Q · filed 2024-08-02 | $46.20M 10-Q · filed 2024-08-02 | $68.11M derived: sum of 3 quarters · filed 2024-08-02 | $87.82M derived: sum of 4 quarters · filed 2024-08-02 | ||
| 2023-03-31 | $22.74M 10-Q · filed 2024-05-03 | $44.64M derived: sum of 2 quarters · filed 2024-05-03 | $64.36M derived: sum of 3 quarters · filed 2024-05-03 | $85.60M derived: sum of 4 quarters · filed 2024-05-03 | ||
| 2022-12-31 | $21.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $41.63M derived: sum of 2 quarters · filed 2024-02-27 | $62.86M derived: sum of 3 quarters · filed 2024-02-27 | $83.11M 10-K · filed 2024-02-27 | ||
| 2022-09-30 | $19.72M 10-Q · filed 2023-11-03 | $40.95M derived: sum of 2 quarters · filed 2023-11-03 | $61.20M 10-Q · filed 2023-11-03 | $80.11M derived: sum of 4 quarters · filed 2023-11-03 | ||
| 2022-06-30 | $21.23M 10-Q · filed 2023-08-04 | $41.48M 10-Q · filed 2023-08-04 | $60.39M derived: sum of 3 quarters · filed 2023-08-04 | $77.08M derived: sum of 4 quarters · filed 2023-08-04 | ||
| 2022-03-31 | $20.25M 10-Q · filed 2023-05-08 | $39.15M derived: sum of 2 quarters · filed 2023-05-08 | $55.84M derived: sum of 3 quarters · filed 2023-05-08 | $74.05M derived: sum of 4 quarters · filed 2023-05-08 | ||
| 2021-12-31 | $18.91M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $35.59M derived: sum of 2 quarters · filed 2023-03-01 | $53.80M derived: sum of 3 quarters · filed 2023-03-01 | $69.87M 10-K · filed 2023-03-01 | ||
| 2021-09-30 | $16.69M 10-Q · filed 2022-11-08 | $34.89M derived: sum of 2 quarters · filed 2022-11-08 | $50.96M 10-Q · filed 2022-11-08 | $64.92M derived: sum of 4 quarters · filed 2022-11-08 | ||
| 2021-06-30 | $18.20M 10-Q · filed 2022-08-08 | $17.62M 10-Q · filed 2021-08-10 | $34.28M 10-Q · filed 2022-08-08 | $33.22M 10-Q · filed 2021-08-10 | $48.24M derived: sum of 3 quarters · filed 2022-08-08 | $59.05M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $16.07M 10-Q · filed 2022-05-09 | $15.60M 10-Q · filed 2021-05-12 | $30.03M derived: sum of 2 quarters · filed 2022-05-09 | $40.84M derived: sum of 3 quarters · filed 2022-05-09 | $51.96M derived: sum of 4 quarters · filed 2022-05-09 | |
| 2020-12-31 | $13.96M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $24.77M derived: sum of 2 quarters · filed 2022-03-01 | $35.88M derived: sum of 3 quarters · filed 2022-03-01 | $46.07M 10-K · filed 2022-03-01 | ||
| 2020-09-30 | $10.81M 10-Q · filed 2021-11-09 | $21.93M derived: sum of 2 quarters · filed 2021-11-09 | $32.11M 10-Q · filed 2021-11-09 | $42.14M derived: sum of 4 quarters · filed 2021-11-09 | ||
| 2020-06-30 | $11.11M 10-Q · filed 2021-08-10 | $21.30M 10-Q · filed 2021-08-10 | $31.32M derived: sum of 3 quarters · filed 2021-08-10 | $39.95M derived: sum of 4 quarters · filed 2021-08-10 | ||
| 2020-03-31 | $10.19M 10-Q · filed 2021-05-12 | $20.21M derived: sum of 2 quarters · filed 2021-05-12 | $28.83M derived: sum of 3 quarters · filed 2021-05-12 | |||
| 2019-12-31 | $10.02M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $18.64M derived: sum of 2 quarters · filed 2021-03-15 | $34.20M 10-K · filed 2021-03-15 | |||
| 2019-09-30 | $8.62M 10-Q · filed 2020-11-13 | $24.18M 10-Q · filed 2020-11-13 | ||||
| 2018-12-31 | $20.35M 10-K · filed 2021-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SkinHealth Systems Inc. (SKIN) | United States | $0.086B | -3.17 |
| LENSAR, Inc. (LNSR) | United States | $0.087B | 2.02 |
| RenovoRx, Inc. (RNXT) | United States | $0.076B | -3.62 |
| Microbot Medical Inc. (MBOT) | $0.089B | -7.97 | |
| FRACTYL HEALTH, INC. (GUTS) | United States | $0.075B | -1.18 |
| CVRx, Inc. (CVRX) | United States | $0.067B | -2.62 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 | |
| TELA Bio, Inc. (TELA) | United States | $0.057B | -0.82 |
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B | |
| Spectral AI, Inc. (MDAI) | United States | $0.052B |